Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cp-724714. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 0.98 |
| ▸ | EGFR | P00533 | 10/20 | 0.98 |
| ▸ | FECH | P22830 | 1/20 | 0.98 |
| ▸ | CDK8 | P49336 | 1/20 | 0.98 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.98 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.98 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-724714 SCHEMBL6169715 | 1.00 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL95109 | 0.99 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL4796165 | 0.99 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL29561705 | 0.99 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL4617807 | 0.99 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL30450143 | 0.99 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168343 | 0.96 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168355 | 0.96 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168463 | 0.96 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168480 | 0.96 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575936-A1 | COMPLEXES OF E-2-METHOXY-N-(3-{4- [3-METHYL-4-(6-METHYL- PYRIDIN -3-YLOXY)-PHENYLAMINO] -QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE, THEIR METHOD OF PRODUCTION, AND USE | Pfizer Products Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| US-20050075354-A1 | Complexes of E-2-Methoxy-N(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinzazolin-6-YL}-allyl)-acetamide, their method of production, and use | PFIZER INC | 2005-04-07 | — | — | US | claimed |
| WO-2004056802-A1 | COMPLEXES OF E-2-METHOXY-N-(3-{4-[3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO]-QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE, THEIR METHOD OF PRODUCTION, AND USE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1575936-A1 | COMPLEXES OF E-2-METHOXY-N-(3-{4- [3-METHYL-4-(6-METHYL- PYRIDIN -3-YLOXY)-PHENYLAMINO] -QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE, THEIR METHOD OF PRODUCTION, AND USE | Pfizer Products Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050075354-A1 | Complexes of E-2-Methoxy-N(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinzazolin-6-YL}-allyl)-acetamide, their method of production, and use | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| WO-2004056802-A1 | COMPLEXES OF E-2-METHOXY-N-(3-{4-[3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO]-QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE, THEIR METHOD OF PRODUCTION, AND USE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075354-A1 | Complexes of E-2-Methoxy-N(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinzazolin-6-YL}-allyl)-acetamide, their method of production, and use | ECI1, CCNA2, ELL | ERBB2 130/4885EGFR 217/4885FECH 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.